Tom 9, Nr 2 (2017)
Artykuły
Opublikowany online: 2017-12-29
Wyświetlenia strony
1140
Wyświetlenia/pobrania artykułu
4940
Zapobieganie ostremu zapaleniu trzustki w czasie cholangiopankreatografii wstecznej ― czy już wszystko jasne?
Gastroenterologia Kliniczna 2017;9(2):33-39.
Streszczenie
Ostre zapalenie trzustki jest najczęstszym powikłaniem cholangiopankreatografii wstecznej występującym u 2–15% wszystkich pacjentów poddawanych tej procedurze. W artykule omówiono postępowanie farmakologiczne, techniki związane z cholangiopankreatografią wsteczną stosowane w celu zredukowania ryzyka jatrogennego ostrego zapalenia trzustki oraz czynniki ryzyka związane z tym powikłaniem. Mechanizmy prowadzące do uszkodzeń tkanek w ostrym zapaleniu trzustki po cholangiopankreatografii wstecznej stanowią kolejne etapy ewolucji procesu zapalnego i mogą potencjalnie stać się celem terapii prewencyjnej. Chociaż stosowanie w badaniach klinicznych wielu cząsteczek wiązało się ze zmniejszeniem ryzyka ostrego zapalenia trzustki po cholangiopankreatografii wstecznej tylko niektóre z nich mają udowodnione działanie w dużych, randomizowanych badaniach. Stosowanie niesteroidowych leków przeciwazaplnych podawanych doodbytniczo należy do potwierdzonych metod prewencji ostrego zapalenie trzustki po cholangiopankreatografii wstecznej. W artykule podjęto próbę określenia i oceny znanych metod stosowanych w celu redukcji ryzyka jatrogennego ostrego zapalenia trzustki.
Słowa kluczowe: cholangiopankreatografia wstecznaOZT po ECPWsfinkterotomia
Referencje
- Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004; 59(7): 845–864.
- Committee ASoP S, Anderson MA, Fisher L, et al. Complications of ERCP. Gastrointest Endosc. 2012; 75: 467–473.
- Kochar B, Akshintala VS, Afghani E, et al. Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials. Gastrointest Endosc. 2015; 81(1): 143–149.e9.
- Elmunzer BJ, Scheiman JM, Lehman GA, et al. U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012; 366(15): 1414–1422.
- Dumonceau JM, Andriulli A, Elmunzer BJ, et al. European Society of Gastrointestinal Endoscopy. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014. Endoscopy. 2014; 46(9): 799–815.
- Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007; 102(8): 1781–1788.
- Banks PA, Bollen TL, Dervenis C, et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013; 62(1): 102–111.
- Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991; 37(3): 383–393.
- Lipinski M, Rydzewska-Rosolowska A, Rydzewski A, et al. Urinary neutrophil gelatinase-associated lipocalin as an early predictor of disease severity and mortality in acute pancreatitis. Pancreas. 2015; 44(3): 448–452.
- Lipinski M, Rydzewska-Rosolowska A, Rydzewski A, et al. Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with acute pancreatitis (AP) - Progress in prediction of AP severity. Pancreatology. 2017; 17(1): 24–29.
- Lipiński M, Rydzewska G. Immature granulocytes predict severe acute pancreatitis independently of systemic inflammatory response syndrome. Prz Gastroenterol. 2017; 12(2): 140–144.
- Cho YS, Kim HK, Jang EC, et al. Usefulness of the Bedside Index for severity in acute pancreatitis in the early prediction of severity and mortality in acute pancreatitis. Pancreas. 2013; 42(3): 483–487.
- Murray B, Carter R, Imrie C, et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003; 124(7): 1786–1791.
- Cheon YK, Cho KB, Watkins JL, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc. 2007; 66(6): 1126–1132.
- Elmunzer BJ, Waljee AK, Elta GH, et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008; 57(9): 1262–1267.
- Khoshbaten M, Khorram H, Madad L, et al. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2008; 23(7 Pt 2): e11–e16.
- Leerhøy B, Nordholm-Carstensen A, Novovic S, et al. Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Scand J Gastroenterol. 2016; 51(8): 1007–1012.
- Luo H, Zhao L, Leung J, et al. Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography: a multicentre, single-blinded, randomised controlled trial. Lancet. 2016; 387(10035): 2293–2301.
- Levenick JM, Gordon SR, Fadden LL, et al. Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients. Gastroenterology. 2016; 150(4): 911–7; quiz e19.
- Patai Á, Solymosi N, Mohácsi L, et al. Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials. Pancreatology. 2017; 17(3): S102–S103.
- Staritz M, Poralla T, Ewe K, et al. Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure. Gut. 1985; 26(2): 194–197.
- Chen B, Fan T, Wang CH. A meta-analysis for the effect of prophylactic GTN on the incidence of post-ERCP pancreatitis and on the successful rate of cannulation of bile ducts. BMC Gastroenterol. 2010; 10: 85.
- Wehrmann T, Schmitt T, Stergiou N, et al. Topical application of nitrates onto the papilla of Vater: manometric and clinical results. Endoscopy. 2001; 33(4): 323–328.
- Bai Y, Xu C, Yang X, et al. Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a meta-analysis of randomized, double-blind, placebo-controlled trials. Endoscopy. 2009; 41(8): 690–695.
- Ding J, Jin Xi, Pan Y, et al. Glyceryl trinitrate for prevention of post-ERCP pancreatitis and improve the rate of cannulation: a meta-analysis of prospective, randomized, controlled trials. PLoS One. 2013; 8(10): e75645.
- Arcidiacono R, Gambitta P, Rossi A, et al. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy. 1994; 26(9): 715–718.
- Katsinelos P, Fasoulas K, Paroutoglou G, et al. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. Endoscopy. 2012; 44(1): 53–59.
- Fluhr G, Mayerle J, Weber E, et al. Pre-study protocol MagPEP: a multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis. BMC Gastroenterol. 2013; 13: 11.
- Smeets XJ, da Costa DW, Besselink MG, et al. Systematic review: periprocedural hydration in the prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther. 2016; 44(6): 541–553.
- Buxbaum J, Yan A, Yeh K, et al. Aggressive hydration with lactated Ringer's solution reduces pancreatitis after endoscopic retrograde cholangiopancreatography. Clin Gastroenterol Hepatol. 2014; 12(2): 303–307.e1.
- Lipinski M, Rydzewska-Rosolowska A, Rydzewski A, et al. Fluid resuscitation in acute pancreatitis: Normal saline or lactated Ringer's solution? World J Gastroenterol. 2015; 21(31): 9367–9372.
- Li S, Cao G, Chen Xi, et al. Low-dose heparin in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2012; 24(5): 477–481.
- Milewski J, Rydzewska G, Degowska M, et al. N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol. 2006; 12(23): 3751–3755.
- Mosler P, Sherman S, Marks J, et al. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc. 2005; 62(2): 245–250.
- Akshintala VS, Hutfless SM, Colantuoni E, et al. Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis. Aliment Pharmacol Ther. 2013; 38(11-12): 1325–1337.
- Katsinelos P, Fasoulas K, Paroutoglou G, et al. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. Endoscopy. 2012; 44(1): 53–59.
- Mok SRS, Ho HC, Shah P, et al. Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial. Gastrointest Endosc. 2017; 85(5): 1005–1013.
- Cheung J, Tsoi KK, Quan WL, et al. Guidewire versus conventional contrast cannulation of the common bile duct for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. Gastrointest Endosc. 2009; 70(6): 1211–1219.
- Tse F, Yuan Y, Bukhari M, et al. Pancreatic duct guidewire placement for biliary cannulation for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Cochrane Database Syst Rev. 2016(5): CD010571.
- Choudhary A, Bechtold ML, Arif M, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc. 2011; 73(2): 275–282.
- Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc. 2009; 70(1): 80–88.
- Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001; 54(4): 425–434.
- Zolotarevsky E, Fehmi SM, Anderson MA, et al. Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial. Endoscopy. 2011; 43(4): 325–330.
